CD4 and Familial prostate cancer: In a report by Santegoets et al. (2013), evaluating combined tumor cell vaccination with ipilimumab in prostate cancer patients, the authors found that elevated frequencies of CD4+CD25hiFoxp3+ Tregs prior to treatment correlated with decreased overall survival following treatment.